# Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

> **NCT07074327** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 74 (actual)

## Conditions studied

- Autosomal Dominant Polycystic Kidney Disease (ADPKD)

## Interventions

- **DRUG:** VX-407
- **DRUG:** LNG/EE
- **DRUG:** NGM/EE
- **DRUG:** NET/EE
- **DRUG:** DRSP/EE

## Key facts

- **NCT ID:** NCT07074327
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-11
- **Primary completion:** 2026-02-20
- **Final completion:** 2026-02-27
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07074327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07074327, "Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07074327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*